FDA-approved drug may block resistance to anti-angiogenesis therapy

September 13, 2017, Massachusetts General Hospital

A Massachusetts General Hospital (MGH) research team has identified a potential strategy for improving the efficacy of angiogenesis inhibitors, drugs that help fight cancer by blocking the formation of new blood vessels. In a follow-up to a study published earlier this year that discovered how anti-angiogenesis treatment can interfere with the immune response against colorectal cancer, the team now describes another pathway that induces an immunosuppressive tumor microenvironment, one that can be blocked with an FDA-approved drug.

"Blocking VEGF signaling - the major target of approved anti-angiogenesis drugs - has shown significant but limited survival benefit for colorectal cancer patients, due to the development of resistance," explains Dai Fukumura, MD, PhD, deputy director of the Edwin L. Steele Laboratories for Tumor Biology in the MGH Department of Radiation Oncology and co-senior author of the current study, which has been published in the online PNAS Early Edition. "By unveiling a previously unknown mechanism of resistance to anti-angiogenic therapy, our findings provide a rapidly translatable strategy to enhancing treatment outcomes."

In their earlier study published in the Journal of Clinical Investigation, the researchers found that angiogenesis inhibitor treatment led to the accumulation of certain innate immune cells - monocytes and neutrophils - in the tumor microenvironment. The early infiltration of a specific subset of cells, called non-classical monocytes, induced the migration of neutrophils and the expression of factors that inhibit the proliferation and function of T cells, blocking the anti-tumor .

While a gene therapy approach to blocking the immunosuppressive pathway identified in the JCI study improved treatment in a mouse model of colorectal cancer, no drug targeting that pathway is currently available, leading the MGH team to search for alternatives. A 2009 study from members of the same team had found that expression of a receptor molecule called CXCR4 and the molecule it binds to, CXCL12, were increased in tumor biopsies from rectal cancer patients treated with anti-VEGF therapy. Since the CXCR4/CXCL12 pathway is known to regulate immune cells, including the more common classical monocytes, the team explored its potential role in the regulation of non-classical monocytes.

After confirming that anti-VEGF therapy increased expression of CXCR4 and CXCL12 in mouse models of colorectal cancer, the team tested the effects of using an FDA-approved CXCR4 inhibitor called AMD3100 or plerixafor to block the pathway. They found that the addition of AMD3100 significantly enhanced the effects of anti-VEGF therapy and alleviated the anti-VEGF-induced reduction in T cells. CXCR4 was found to be expressed primarily on monocytes and neutrophils in the , and blocking the pathway with AMD3100 reduced the infiltration of immunosuppressive non-classical monocytes and neutrophils, improving treatment efficacy.

"We anticipate that these novel findings on the immunosuppressive role of non-classical monocytes in will trigger follow-up studies in other types of , as well as in inflammatory diseases, leading to the development of multiple therapeutic regimens," says Fukumura, an associate professor of Radiation Oncology at Harvard Medical School (HMS).

Rakesh K. Jain, PhD - director of the Steele Labs, Cook Professor of Radiation Oncology (Tumor Biology) at HMS, and co-senior author of the PNAS paper - adds, "While AMD3100 treatment abolished anti-VEGF-induced innate immune cell accumulation, it did not affect basal levels of these important cells, which supports the favorable safety profile of this agent and should facilitate clinical translation."

Explore further: Immunosuppression underlies resistance to anti-angiogenic therapy

More information: Keehoon Jung et al, Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1710754114

Related Stories

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...

Targeting two angiogenesis pathways could improve results of glioblastoma treatment

April 4, 2016
Two companion papers from Massachusetts General Hospital (MGH) research teams suggest that targeting multiple angiogenesis pathways simultaneously could help overcome the resistance to anti-angiogenic treatment inevitably ...

Penn researchers help unravel mysteries of pancreatic cancer's resistance to standard therapies

January 24, 2017
Pancreatic cancer has long been one of the hardest to treat. Now, in a new study, researchers at the Perelman School of Medicine at the University of Pennsylvania have illuminated one of this cancer's major resistance mechanisms: ...

Brain microenvironment makes HER2-positive breast cancer metastases resistant to treatment

May 24, 2017
While target therapies directed toward genetic mutations that drive a tumor's growth have significantly improved the outlook for many patients, they have not been as successful in controlling brain metastases in several types ...

Combination treatment may improve survival of breast cancer patients with brain metastases

November 1, 2012
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts ...

Study finds mechanism by which obesity promotes pancreatic and breast cancer

February 12, 2016
Massachusetts General Hospital (MGH) investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, ...

Recommended for you

Research team discovers drug compound that stops cancer cells from spreading

June 22, 2018
Fighting cancer means killing cancer cells. However, oncologists know that it's also important to halt the movement of cancer cells before they spread throughout the body. New research, published today in the journal Nature ...

Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant

June 21, 2018
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018
A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Higher body fat linked to lower breast cancer risk in younger women

June 21, 2018
While obesity has been shown to increase breast cancer risk in postmenopausal women, a large-scale study co-led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher found the opposite is true ...

Researchers uncover new target to stop cancer growth

June 21, 2018
Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes—tiny, membrane-bound packages containing proteins and RNAs that stimulate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.